Rondot P, Ziegler M, Aymard N, Holzer J
Service de Neurologie, CHSA, Centre Raymond Garcin, Paris.
Rev Neurol (Paris). 1987;143(11):746-52.
Twenty-five patients, 12 men and 13 women, 42 to 79 years (mean 62) were studied to determine possible interest of a controlled release preparation of L. dopa combined with benserazide. All patients were experiencing fluctuations in efficacy over the last 8 +/- 4 years. Their Parkinson disease was of long duration, (16 +/- 5 years), severe (Hoehn and Yahr's stages III to V) and treated with L. dopa for 12 +/- 4 years. Results were evaluated in the short, medium and long term. During the initial period the new treatment was substituted for previous therapy on a dose for dose basis. Long term (300 days) results showed that "end of dose" fluctuations had been improved in 40 p. 100 of cases without concomitant reduction in therapeutic effects, duration of "ON" periods progressing by 60%. The frequency of drug intake was unaltered but daily dosage could be increased by 30% without increasing severity of abnormal movements to a similar degree. The administration of this new presentation can be recommended, especially when frequent fluctuations compromise long term therapeutic effects.
对25名患者（12名男性和13名女性，年龄42至79岁，平均62岁）进行了研究，以确定左旋多巴与苄丝肼控释制剂的潜在益处。所有患者在过去8±4年中疗效均有波动。他们患帕金森病的时间较长（16±5年），病情严重（Hoehn和Yahr分期为III至V期），且接受左旋多巴治疗12±4年。对结果进行了短期、中期和长期评估。在初始阶段，新治疗方案在剂量对等的基础上替代了先前的治疗。长期（300天）结果显示，40%的病例“剂末”波动得到改善，且治疗效果未同时降低，“开”期时长增加了60%。服药频率未改变，但每日剂量可增加30%，而异常运动的严重程度不会增加到类似程度。推荐使用这种新剂型，尤其是当频繁波动影响长期治疗效果时。
